Literature DB >> 22005063

Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway.

Wenrong Gong1, Qibin Song, Xiaoming Lu, Wensheng Gong, Jianhua Zhao, Peng Min, Xianjin Yi.   

Abstract

In this study, we investigated the mechanisms by which the chemotherapeutic agent paclitaxel (PTX) induced the expression of B7-H1 immunosuppressive molecules in the human colorectal adenocarcinoma cell line SW480 and the hepatocellular carcinoma cell line HepG2. We found ptX induced B7-H1 protein expression in SW480 and HepG2 cells as demonstrated by immunofluorescence and flow cytometry and mRNA expression by using real-time quantitative polymerase chain reaction (PCR). Moreover, PTX treatment induced Erk½ phosphorylation in both cell lines. PTX-increased B7-H1 mRNA expression was significantly blocked by MEK inhibitor U0126. However, the protein expression caused by PTX was only partially blocked by U0126. Our results suggest that PTX upregulated B7-H1 expression in cultured SW480 and HepG2 cells via both transcriptional and post-transcriptional mechanisms. This may help us better understand PTX-related tumor immune evasion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005063     DOI: 10.1179/joc.2011.23.5.295

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  18 in total

1.  Mitogen-activated protein kinase inhibition enhances the antitumor effects of sporamin in human pancreatic cancer cells.

Authors:  Cui-Juan Qian; Yong-Xiao Qi; Sheng Zhong; Ju-Ping Zeng; Xiao-Ying Chen; Jun Yao
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

Review 2.  Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death.

Authors:  Kannan Badri Narayanan; Manaf Ali; Barry J Barclay; Qiang Shawn Cheng; Leandro D'Abronzo; Rita Dornetshuber-Fleiss; Paramita M Ghosh; Michael J Gonzalez Guzman; Tae-Jin Lee; Po Sing Leung; Lin Li; Suidjit Luanpitpong; Edward Ratovitski; Yon Rojanasakul; Maria Fiammetta Romano; Simona Romano; Ranjeet K Sinha; Clement Yedjou; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Dustin G Brown; Elizabeth P Ryan; Annamaria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Hosni K Salem; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Seo Yun Kim; William H Bisson; Leroy Lowe; Hyun Ho Park
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

3.  DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.

Authors:  Gulzar Ahmad; Gerardo G Mackenzie; James Egan; Mansoor M Amiji
Journal:  Mol Cancer Ther       Date:  2019-08-22       Impact factor: 6.261

4.  Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.

Authors:  Q Sheng; Y Zhang; Z Wang; J Ding; Y Song; W Zhao
Journal:  Clin Exp Immunol       Date:  2019-12-27       Impact factor: 4.330

5.  5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.

Authors:  Lauren Van Der Kraak; Gaurav Goel; Rajeev Dhupar; Michael T Lotze; Krishnaveni Ramanan; Christof Kaltenmeier; Lin Zhang; Daniel P Normolle; Gordon J Freeman; Daolin Tang; Katie S Nason; Jon M Davison; James D Luketich
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

Review 6.  The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy.

Authors:  Jessica Ann Chacon; Keith Schutsky; Daniel J Powell
Journal:  Vaccines (Basel)       Date:  2016-11-14

7.  Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection.

Authors:  Mi Jung Kwon; Kab-Choong Kim; Eun Sook Nam; Seong Jin Cho; Hye-Rim Park; Soo Kee Min; Jinwon Seo; Ji-Young Choe; Hye Kyung Lee; Ho Suk Kang; Kyueng-Whan Min
Journal:  Oncotarget       Date:  2017-07-19

8.  Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.

Authors:  M Wangpaichitr; H Kandemir; Y Y Li; C Wu; Djm Nguyen; L G Feun; M T Kuo; N Savaraj
Journal:  Cell Dev Biol       Date:  2017-04-28

9.  Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

Authors:  Edwin R Parra; Pamela Villalobos; Carmen Behrens; Mei Jiang; Apar Pataer; Stephen G Swisher; William N William; Jiexin Zhang; Jack Lee; Tina Cascone; John V Heymach; Marie-Andrée Forget; Cara Haymaker; Chantale Bernatchez; Neda Kalhor; Annikka Weissferdt; Cesar Moran; Jianjun Zhang; Ara Vaporciyan; Don L Gibbons; Boris Sepesi; Ignacio I Wistuba
Journal:  J Immunother Cancer       Date:  2018-06-06       Impact factor: 13.751

10.  The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.

Authors:  Yu Wang; Qingguo Sun; Ning Mu; Xiaoyang Sun; Yingying Wang; Songqing Fan; Ling Su; Xiangguo Liu
Journal:  Cell Commun Signal       Date:  2020-07-14       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.